



US005935993A

United States Patent [19]

Tang et al.

[11] Patent Number: 5,935,993

[45] Date of Patent: Aug. 10, 1999

[54] TYRPHOSTIN LIKE COMPOUNDS

[75] Inventors: **Peng Cho Tang**, Moraga; **Li Sun**, Foster City; **Asaad S. Nematalla**, Walnut Creek; **Gerald McMahon**, Kenwood, all of Calif.

[73] Assignee: **Sugen, Inc.**, Redwood City, Calif.

[21] Appl. No.: 08/957,420

[22] Filed: Oct. 24, 1997

Related U.S. Application Data

- [63] Continuation of application No. 08/480,275, Jun. 7, 1995, abandoned.
- [51] Int. Cl.⁶ C07D 333/34; C07D 307/64; A61K 31/38
- [52] U.S. Cl. 514/445; 514/473; 549/65; 549/479; 549/475
- [58] Field of Search 549/65, 475, 479; 514/445, 473

[56] **References Cited**

U.S. PATENT DOCUMENTS

| | | | | |
|-----------|---------|-------------------|-------|---------|
| 4,966,849 | 10/1990 | Vallee et al. | | 435/199 |
| 5,217,999 | 6/1993 | Levitzki et al. | | 514/613 |
| 5,302,606 | 4/1994 | Spada et al. | | 514/357 |
| 5,330,992 | 7/1994 | Eissenstat et al. | | 514/312 |

FOREIGN PATENT DOCUMENTS

| | | | |
|-------------|---------|----------------------|--|
| 566 266 | 10/1993 | European Pat. Off. . | |
| WO 91/15495 | 10/1991 | WIPO . | |
| WO 92/20642 | 11/1992 | WIPO . | |
| WO 92/21660 | 12/1992 | WIPO . | |
| WO 94/03427 | 2/1994 | WIPO . | |
| WO 94/10202 | 5/1994 | WIPO . | |
| WO 94/14808 | 7/1994 | WIPO . | |

OTHER PUBLICATIONS

- Aaronson, S. A. (1991). Growth factors and cancer. *Science* 254, 1146–1153.
- Arvidsson, A.-K., et al. (1994). Tyr-716 in the platelet-derived growth factor b-receptor kinase insert is involved in GRB2 binding and ras activation. *Molecular and Cellular Biology* 14, 6715–6726.
- Baserga, R. (1995). The insulin-like growth factor I receptor: a key to tumor growth? *Cancer Research* 55, 249–252.
- Bisbee, C. (1995). Scatter factor/hepatocyte growth factor gene deletion leads to death in knockout mice. *BioWorld Today* 24 Feb. 1995, 2.
- Carraway, L. K., et al. (1994). The erbB3 Gene Product Is a Receptor for Heregulin. *The Journal of Biological Chemistry* 269, 14303–14306.
- Carraway, K. L. and Cantley, L. C. (1994). A Neu Acquaintance for ErbB3 and ErbB4: A role for receptor heterodimerization in growth signaling. *Cell* 78, 5–8.
- Claesson-Welsh, L. (1994). Signal transduction by the PDGF receptors. *Progress in Growth Factor Research* 5, 37–54.
- Cullen, K. J., Yee, D., and Rosen, N. (1991). Insulinlike Growth Factors in Human Malignancy. *Cancer Investigation* 9, 443–454.
- Dati, C., Antoniotti, S., Taverna, D., Perroteau, I., and De Bortoli, M. (1990). Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. *Oncogene* 5, 1001–1006.
- Decker, T., and Lohmann-Matthes, M.-L. (1988). A quick and simple method for quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. *J. of Imm. Methods* 15, 61–69.
- de Vries, C., Escobedo, J. A., Ueno, H., Houck, K., Ferrara, N., and Williams, L. T. (1992). The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. *Science* 255, 989–991.
- Dougall, W. C., Qian, X., Peterson, N. C., Miller, M. J., Samanta, A., and Greene, M. I. (1994). The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. *Oncogene* 9, 2109–2123.
- Fendly, B. M. (1990). Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. *Cancer Research* 50, 1550–1558.
- Ferrara, N., and Henzel, W. J. (1989). Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. *Biochemical and Biophysical Research Communications* 161, 851–858.
- Fingl, E., and Woodbury, D. M. (1975). The Pharmacological Basis of Therapeutics Chapter I, 1–46.
- Floeger, J., Eng, E., Young, B. A., and Johnson, R. J. (1993). Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo. *Kidney International* 43, S-47 –S-54.
- Folkman, J. (1971). Tumor Angiogenesis: therapeutic implications. *The New England Journal of Medicine* v. 285, 18 Nov. 1971, 1182–1186.
- Folkman, J. (1990). What is the evidence that tumors are angiogenesis dependent? *Journal of the National Cancer Institute* 82, 4–6.
- Folkman, J., and Shing, Y. (1992). Angiogenesis. *The Journal of Biological Chemistry* 267, 10931–10934.
- Fry, M. J., Panayotou, G., Booker, G. W., and Waterfield, M. D. (1993). New insights into protein–tyrosine kinase receptor signaling complexes. *Protein Science* 2, 1785–1797.
- Giordano, S., Di Renzo, M. F., Olivero, M., Mondino, A., Zhen, Z., Medicò, E., and Comoglio, P. M. (1992). The c-met/HGF receptor in human tumours. *European Journal of Cancer Prevention* 1, 45–49.

(List continued on next page.)

Primary Examiner—Alan L. Rotman

Attorney, Agent, or Firm—Lyon & Lyon LLP

[57]

ABSTRACT

The present invention relates to molecules capable of modulating tyrosine signal transduction to prevent and treat cell proliferative disorders or cell differentiation disorders associated with particular tyrosine kinases by inhibiting one or more abnormal tyrosine kinase activities.

16 Claims, No Drawings